PURPOSE: The present retrospective study assessed the role of proton beam therapy (PBT) in the treatment of patients with Stage II or III non-small-cell lung cancer who were inoperable or ineligible for chemotherapy because of co-existing disease or refusal. PATIENTS AND METHODS: Between November 2001 and July 2008, PBT was given to 35 patients (5 patients with Stage II, 12 with Stage IIIA, and 18 with Stage IIIB) whose median age was 70.3 years (range, 47.4-85.4). The median proton dose given was 78.3 Gy (range, 67.1-91.3) (relative biologic effectiveness). RESULTS: Local progression-free survival for Stage II-III patients was 93.3% at 1 year and 65.9% at 2 years during a median observation period of 16.9 months. Four patients (11.4%) developed local recurrence, 13 (37.1%) developed regional recurrence, and 7 (20.0%) developed distant metastases. The progression-free survival rate for Stage II-III patients was 59.6% at 1 year and 29.2% at 2 years. The overall survival rate of Stage II-III patients was 81.8% at 1 year and 58.9% at 2 years. Grade 3 or greater toxicity was not observed. A total of 15 patients (42.9%) developed Grade 1 and 6 (17.1%) Grade 2 toxicity. CONCLUSION: PBT for Stage II-III non-small-cell lung cancer without chemotherapy resulted in good local control and low toxicity. PBT has a definite role in the treatment of patients with Stage II-III non-small-cell lung cancer who are unsuitable for surgery or chemotherapy.
PURPOSE: The present retrospective study assessed the role of proton beam therapy (PBT) in the treatment of patients with Stage II or III non-small-cell lung cancer who were inoperable or ineligible for chemotherapy because of co-existing disease or refusal. PATIENTS AND METHODS: Between November 2001 and July 2008, PBT was given to 35 patients (5 patients with Stage II, 12 with Stage IIIA, and 18 with Stage IIIB) whose median age was 70.3 years (range, 47.4-85.4). The median proton dose given was 78.3 Gy (range, 67.1-91.3) (relative biologic effectiveness). RESULTS: Local progression-free survival for Stage II-III patients was 93.3% at 1 year and 65.9% at 2 years during a median observation period of 16.9 months. Four patients (11.4%) developed local recurrence, 13 (37.1%) developed regional recurrence, and 7 (20.0%) developed distant metastases. The progression-free survival rate for Stage II-III patients was 59.6% at 1 year and 29.2% at 2 years. The overall survival rate of Stage II-III patients was 81.8% at 1 year and 58.9% at 2 years. Grade 3 or greater toxicity was not observed. A total of 15 patients (42.9%) developed Grade 1 and 6 (17.1%) Grade 2 toxicity. CONCLUSION: PBT for Stage II-III non-small-cell lung cancer without chemotherapy resulted in good local control and low toxicity. PBT has a definite role in the treatment of patients with Stage II-III non-small-cell lung cancer who are unsuitable for surgery or chemotherapy.
Authors: Y Hatayama; T Nakamura; M Suzuki; Y Azami; T Ono; H Yamaguchi; Y Hayashi; I Tsukiyama; M Hareyama; Y Kikuchi; Y Takai Journal: Curr Oncol Date: 2015-10 Impact factor: 3.677
Authors: Quynh-Nhu Nguyen; Ngoc Bui Ly; Ritsuko Komaki; Lawrence B Levy; Daniel R Gomez; Joe Y Chang; Pamela K Allen; Reza J Mehran; Charles Lu; Michael Gillin; Zhongxing Liao; James D Cox Journal: Radiother Oncol Date: 2015-05-28 Impact factor: 6.280
Authors: Joe Y Chang; Ritsuko Komaki; Charles Lu; Hong Y Wen; Pamela K Allen; Anne Tsao; Michael Gillin; Radhe Mohan; James D Cox Journal: Cancer Date: 2011-03-22 Impact factor: 6.860
Authors: Aparna H Kesarwala; Christine J Ko; Holly Ning; Eric Xanthopoulos; Karl E Haglund; William P O'Meara; Charles B Simone; Ramesh Rengan Journal: Clin Lung Cancer Date: 2014-12-09 Impact factor: 4.785
Authors: Alexander Chi; Nam Phong Nguyen; James S Welsh; William Tse; Manish Monga; Olusola Oduntan; Mohammed Almubarak; John Rogers; Scot C Remick; David Gius Journal: Front Oncol Date: 2014-06-20 Impact factor: 6.244